BIOMX INC. DL -,0001

Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance Corporate Presentation June 2025 aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); NYSE American: PHGE Opportunity: Clinical stage programs targeting a critical threat to the global healthcare system - antibiotic resistance Phage Therapy Promise Alarming rise in antimicrobial resistance signals urgent need for better treatment Phage therapy emerging as a powerful solution for persistent infections, supported by growing body of efficacy and safety data BX211 - S. aureus infections Positive efficacy and safety data (Phase 2) in DFI & DFO with S. aureus infection, showing sustained ulcer reduction and superior recovery outcomes in bone-depth ulcers Potential additional Phase 2 ready indications: PJI BX004 - P. aeruginosa infections Positive Phase 1b/2a data in CF patients with P. aeruginosa infection, demonstrating sputum culture conversion, improved lung function, and bacterial reduction Phase 2b study ongoing Potential additional Phase 2 ready indications: NCFB, HAP/VAP DFI: Diabetic Foot Infection; DFO: Diabetic Foot Osteomyelitis; PJI: Prosthetic Joint Infection 3 CF: Cystic Fibrosis; NCFB: Non-cystic Fibrosis Bronchiectasis; HAP/HVP: Hospital-acquired / Ventilator-associated Pneumonia Antimicrobial Resistance: Rising concerns and limited treatment options underscore the urgent need for novel therapies 42% 35% 70% >2x Resistance Rate for Cephalosporin-resistant E. coli1 Resistance Rate for Methicillin-resistant S. aureus1 Increase in Death Associated with Antimicrobial Resistance Expected by 20502 Increase in Death Associated with Antibiotic Resistant S. aureus from 1990 to 20212 10M Annual Deaths by 2050 WHO projected Antimicrobial Resistance Mortality3 $100T Drug Resistant Infection Cumulative Economic Loss by 20504 World Health Organization (2022). Global antimicrobial resistance and use surveillance system (GLASS) report: 2022. GBD 2021 Antimicrobial Resistance Collaborators (2024). Lancent. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050 4 World Health Organization. (2019, April 29). New report calls for urgent action to avert antimicrobial resistance crisis O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance Phage Therapy: A century-old solution with renewed promise Key Advantages Active against Antibiotic Resistant Strains Safe Modality, Inert to Human Cells, and Supported by FDA No Disruption to Microbiome -Targets Only Harmful Bacteria Penetrates and Disrupts Biofilm Self-Amplifying Phages Increase Efficacy of Each Dose Ability to Launch Straight into Early/Mid Clinical Development Though first discovered >100 years ago, phage therapy struggled to gain traction-now, with rising antibiotic resistance and recent positive clinical data, we believe that its breakthrough moment has finally arrived 5 Attention: This is an excerpt of the original content. To continue reading it, access the original document here. AttachmentsOriginal documentPermalinkDisclaimer BiomX Inc. published this content on June 09, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 09, 2025 at 14:01 UTC.» Mehr auf marketscreener.com

Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)» Mehr auf globenewswire.com

BiomX Inc. (NYSE:PHGE ) Q1 2025 Earnings Conference Call May 15, 2025 2:00 PM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Yale Jen - Laidlaw & Company Operator Greetings and welcome to the BiomX First Quarter 2025 Financial Results Conference Call.» Mehr auf seekingalpha.com